

Company registration number: 8180701

Charity registration number: 1157635

Melanoma UK Limited

(A company limited by guarantee)

Annual Report and Financial Statements

for the Year Ended 31 August 2024

Beever and Struthers
One Express
1 George Leigh Street
Manchester
M4 5DL

Melanoma UK Limited

Contents

Reference and Administrative Details	1
Trustees' Report	2 to 6
Independent Examiner's Report	7
Statement of Financial Activities	8
Balance Sheet	9
Notes to the Financial Statements	10 to 20

Melanoma UK Limited

Reference and Administrative Details

Chief Executive Officer	Mark Rawden (ceased 31 October 2024)
Trustees	David Bridge Adrian Carroll Paula Bridge
Principal Office	Adamson House The Towers Business Park Didsbury Manchester M20 2YY
Registered Office	C/o Beever and Struthers One Express 1 George Leigh Street Manchester M4 5DL
Company Registration Number	8180701
Charity Registration Number	1157635
Independent Examiner	Beever and Struthers One Express 1 George Leigh Street Manchester M4 5DL

Melanoma UK Limited

Trustees' Report

The trustees present their annual report together with the financial statements of the Company for the year ended 31 August 2024. The annual report serves the purposes of both a Trustees' report and a directors' report under company law. The Trustees confirm that the annual report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (second edition of the Charities SORP (FRS102) October 2019, effective 1 January 2019).

Since the Company qualifies as small under section 382 of the Companies Act 2006, the Strategic Report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.

Objectives and activities

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'.

The objects of Melanoma UK Incorporating Factor 50 (hereinafter referred to as Melanoma UK) as set out in its Memorandum of Association are to:

1. To provide patient support and assist in the awareness of the condition Malignant Melanoma.
2. To provide funds for vital research with regards to the development of drugs to prolong and preserve quality of life.
3. To educate and increase awareness of the dangers of Melanoma.

We have developed 2 vision/mission statements to help us remain focused within our activities.

Our Vision is to make a difference in the fight against melanoma by supporting advancements in prevention, treatment, and cure. By raising funds and awareness, we will help individuals to be proactive with early detection and provide information about diagnosis, treatment and support through their journey with Melanoma

Our Mission is to provide support, education, and advocacy for those directly and indirectly impacted by Melanoma, in collaboration and alignment with professionals working in the field of diagnosis, treatment and research. Our core focus is to help promote skin health by reducing the instances and impact of this largely avoidable skin cancer.

Strategic Objectives

1. Raise funds to support the prevention, treatment and cure of Melanoma
2. Increase public awareness through education about Melanoma.
3. Provide financial support for research and collaboration
4. Ensure accessible reliable information for individuals affected by Melanoma
5. Advocacy and policy influence:

Melanoma UK Limited

Trustees' Report

Review of activities

From a modest level of fundraising activity at the end of 2023 we have worked hard to increase levels throughout 2024 and into 2025.

We had our very successful Beauty Spotters campaign which was launched in May 2024 where we focused on the beauty industry highlighting the risks of Aclal melanoma within the Black and Brown communities. This got a lot of exposure from the main tabloids and magazines such as Cosmopolitan and Women's Health

This was closely followed by the "1804 Garden", the headlining show garden, which featured at RHS Tatton Garden show in July 2024 . The design by Carolyn Harden and Jon Jarvis won a silver award at the show for its intuitive design highlighting skin cancer and the link between physical and mental health. The Melanoma team were on hand every day to engage with the public offering advice on safe sun.

After Tatton a scaled down version was on show at the Southport flower show before being finally donated to Lancashire and South Cumbria NHS Foundation Trust to be used as a well being garden for mental health patients and NHS workers.

On the back of last years very successful awareness campaigns we have continued our partnership with Jewson Builder's merchants, one of the largest builders merchants in the UK. We were invited to attend and provide speakers for numerous live events across the country.

We are delighted to confirm that we been able to place another Horus 800 mole mapping machine this time within the Norfolk and Norwich University Hospital which will enable them to supply to patients across the region and will help identify issues earlier and receive treatment sooner which will ultimately save lives. The machine was donated in memory of Neil Evans by the funds raised by his family and friends and we were delighted to meet his family for the unveiling of the plaque recognizing the donation in Neil's memory.

We were delighted to see our Ambassador David Utterly scale the heights of Kilimanjaro for a second time in aid of Melanoma UK. David's support with fundraising , giving talks and appearing on radio interviews has been amazing over the last year and is greatly appreciated by all.

We have worked closely with the team at Run for Charity and on the back of receiving more applications to support Melanoma UK have secured 5 places for the London Landmarks , 15 runners for the Hackney Half marathon and we are delighted to have secured a place in the London Marathon for 2025

The Charity's lottery was relaunched as the "1804" (recognizing the year Melanoma was first mentioned in medical journals) and our general appeal for use of funds wherever the need is greatest along with individual fundraiser activity have positively impacted the charity funds.

Improved awareness is being pushed on several fronts via Website & SM activity, partnerships, connections with professional organisations, clinicians and now recently government (via MUK presence at a parliamentary round table in March which is expected to develop further). There has been some good work on education/ awareness materials and increased connections with other Charities.

Recently MUK joined One Cancer Voice via Cancer 52, calling on the UK government for more investment to fully fund the national Cancer Plan. This was shared across media.

Another positive development on this objective is recent invite and attendance of a Parliamentary roundtable on UV safety linked to Sunbeds. This is expected to develop into a joint campaign including respected representatives from across the Beauty industry and media. The potential outcomes of this could lead to better awareness and hopefully control and legislation (including Gov Health warnings at point of use).

Melanoma UK Limited

Trustees' Report

Financial review

The charity's income is mainly from donations and discretionary sponsorship. Income for the year was £285,944 (2023: £455,227) with restricted income equating to £nil (2023 - £nil) and unrestricted to £285,944 (2023: £455,227).

At the end of the year there were total funds of £310,653 (2023: £265,822) comprising £4,562 (2023: £4,562) of restricted funds and £306,091 (2023: £261,260) of unrestricted funds.

Amounts held in fixed assets were £2,790 leaving £307,863 in free reserves.

Despite the difficulties experienced by the impact of Covid -19 and the current Public enquiry the Trustees have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future and are optimistic about its position going forward having secured new partnerships which will benefit the charity going forward.

We have improved control on spend with updated financial policies and tighter expenses management, unrequired services have been terminated and settlement of outstanding/ disputed charges have helped rationalize the accounting process leading to lower financial accounting and legal costs moving forward. Quarterly Financial updates are in place with our external accountants, including financial outlook benchmarking.

MUK has made solid progress across its strategic objectives, particularly in partnerships, fundraising structure, public awareness, and advocacy. Continued focus on corporate engagement, structured fundraising, and policy influence will be key to maintaining momentum.

With the evolution, stabilisation and development of the Charity, MUK is becoming better placed to engage with external organisations and progress is being made in this area. Connections with NHS parties, Cancer 52 and others have been remade and confidence is growing. With a larger, increasingly diverse and experienced Trustee team, coupled with renewed senior management and CEO leadership, MUK is becoming better placed to have a 'voice at the table' in Melanoma related matters.

Policy on reserves

The Trustees aim to maintain reserves in unrestricted funds at a desired level of £100,000, This level of reserves is considered to be reasonable to support the charity's ongoing commitments.

At the financial year end, Melanoma UK's reserves were higher than the stated reserves policy of £100,000.

Plans for future periods

Aims and key objectives for future periods

The current Trustees intend to expand the board of Trustees to add specific skill sets, to increase Trustee involvement and supervision who will compliment the scheme of delegation which has been devised. The fundamentals of the Charity will be maintained and strengthened. The Charity will continue to reduced expense levels by moving to a virtual platform following the closure of the physical office which will enable it to devote more time and funds to the charitable aims. The charity has a wealth of support and a genuine reason to thrive.

Going concern

The Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future.

Melanoma UK Limited

Trustees' Report

Structure, governance and management

Melanoma UK is registered as a charitable company limited by guarantee and was set up by a Memorandum of Association on 15/08/2012, and the Articles were since amended by a special resolution passed on 27/05/2014 with charity registration number 1157635.

Recruitment and appointment of trustees

The company is the responsibility of the trustees who are elected in accordance with the terms in its Memorandum of Association. The Trustees are legally responsible for managing, controlling, and directing the affairs of their charity. All directors of the company are also trustees of the charity, and there are no other trustees. The trustees named below served in the year. The board has the power to appoint additional trustees as it considers fit to do so based on their suitability for the role. A board skills audit was undertaken with a view to expand the skillset of the board and recruitment is ongoing.

The Trustees who served during the year were: -

Mrs Paula Bridge
Mr David Bridge
Mr Adrian Carroll

Organisational structure

People support has improved with the full time Administration role ensuring timely responses to enquiries (including signposting) as well as consistent support and thank you communications for donations and fundraisers. Lindsey Brough is assisted by Deborah Thomassen who continues in a part-time capacity to lend support and HR guidance.

We bid farewell to our interim CEO Mark Rawden and welcomed our new permanent CEO Tracy Paine MBE who has a wealth of experience in the charity sector. She is ably assisted in the management of the Charity by Colin Glover our COO who has had a huge impact on the internal functions and governance within the Charity.

Melanoma UK Limited

Trustees' Report

Statement of Trustees' Responsibilities

The trustees (who are also the directors of Melanoma UK Limited for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The annual report was approved by the trustees of the charity on17/04/25..... and signed on its behalf by:

David Bridge
.....
David Bridge
Trustee

Melanoma UK Limited

Independent Examiner's Report to the trustees of Melanoma UK Limited

I report on the accounts of the charity for the year ended 31 August 2024 which are set out on pages 8 to 20 .

Respective responsibilities of trustees and examiner

The trustees (who are also the directors of the company for the purposes of company law) are responsible for the preparation of the accounts. The trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed. The charity's gross income exceeded £250,000 and I am qualified to undertake the examination by being a qualified member of ICAEW .

Having satisfied myself that the charity is not subject to audit under company law and is eligible for independent examination, it is my responsibility to:

- examine the accounts under section 145 of the 2011 Act;
- to follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and
- to state whether particular matters have come to my attention.

Basis of independent examiner's report

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a 'true and fair view' and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no matter has come to my attention:

(1) which gives me reasonable cause to believe that in any material respect the requirements:

- to keep accounting records in accordance with section 386 of the Companies Act 2006; and
- to prepare accounts which accord with the accounting records, comply with the accounting requirements of section 396 of the Companies Act 2006 and with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities

have not been met; or

(2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



.....
Helen Binns FCA
ICAEW

One Express
1 George Leigh Street
Manchester
M4 5DL

Date: 17 April 2025.....

Melanoma UK Limited

Statement of Financial Activities for the Year Ended 31 August 2024 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted funds £	Restricted funds £	Total 2024 £
Income and Endowments from:				
Donations and legacies	3	267,102	-	267,102
Other trading activities	4	11,489	-	11,489
Investment income	5	7,353	-	7,353
Total Income		285,944	-	285,944
Expenditure on:				
Charitable activities	6	241,113	-	241,113
Total Expenditure		241,113	-	241,113
Net income		44,831	-	44,831
Net movement in funds		44,831	-	44,831
Reconciliation of funds				
Total funds brought forward		261,260	4,562	265,822
Total funds carried forward	16	306,091	4,562	310,653

	Note	Unrestricted funds £	Restricted funds £	Total 2023 £
Income and Endowments from:				
Donations and legacies	3	418,837	-	418,837
Other trading activities	4	30,661	-	30,661
Investment income	5	5,729	-	5,729
Total Income		455,227	-	455,227
Expenditure on:				
Charitable activities	6	557,274	-	557,274
Total Expenditure		557,274	-	557,274
Net expenditure		(102,047)	-	(102,047)
Transfers between funds		40,050	(40,050)	-
Net movement in funds		(61,997)	(40,050)	(102,047)
Reconciliation of funds				
Total funds brought forward		323,257	44,612	367,869
Total funds carried forward	16	261,260	4,562	265,822

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2023 is shown in note 16.

Melanoma UK Limited
(Registration number: 8180701)
Balance Sheet as at 31 August 2024

	Note	2024 £	2023 £
Fixed assets			
Tangible assets	12	2,790	29,865
Current assets			
Stocks	13	8,985	-
Debtors	14	70,549	77,746
Cash at bank and in hand		260,074	426,558
		339,608	504,304
Creditors: Amounts falling due within one year	15	(31,745)	(268,347)
Net current assets		307,863	235,957
Net assets		310,653	265,822
Funds of the charity:			
Restricted funds		4,562	4,562
Unrestricted income funds			
Unrestricted funds		306,091	261,260
Total funds	16	310,653	265,822

For the financial year ending 31 August 2024 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the charity to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements on pages 8 to 20 were approved by the trustees, and authorised for issue on 17.04.25 and signed on their behalf by:

David Bridge

David Bridge
Trustee

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

1 Charity status

The charity is a charity limited by guarantee and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £10 towards the assets of the charity in the event of liquidation.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Basis of preparation

Melanoma UK Limited meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Exemption from preparing a cash flow statement

The charity opted to early adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

Income and endowments

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the charity before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that these conditions will be fulfilled in the reporting period.

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

Investment income

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs

Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, for example, allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.

Governance costs

These include the costs attributable to the charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees' meetings and reimbursed expenses.

Taxation

The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Tangible fixed assets

Individual fixed assets are initially recorded at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class	Depreciation method and rate
Motor vehicles	25% reducing balance
Fixtures, fittings and equipment	20% straight line
Office equipment	20% straight line

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

Stock

Stock is valued at the lower of cost and estimated selling price less costs to complete and sell, after due regard for obsolete and slow moving stocks. Cost is determined using the first-in, first-out (FIFO).

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the charity does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.

Designated funds are unrestricted funds earmarked by the trustees for particular future project or commitment.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

Recognition and measurement

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

3 Income from donations and legacies

	Unrestricted funds		
	General	Total	Total
	£	2024	2023
		£	£
Donations and legacies;			
Donations from individuals	256,690	256,690	358,700
Gift aid reclaimed	10,412	10,412	60,137
	<u>267,102</u>	<u>267,102</u>	<u>418,837</u>

4 Income from other trading activities

	Unrestricted funds		
	General	Total	Total
	£	2024	2023
		£	£
Trading income;			
Shop income from sale of donated goods and services	-	-	11,208
Lotteries and competitions income	11,489	11,489	19,453
	<u>11,489</u>	<u>11,489</u>	<u>30,661</u>

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

5 Investment income

	Unrestricted funds		
	General	Total	Total
	£	2024	2023
		£	£
Interest receivable and similar income;			
Other interest receivable	7,353	7,353	5,729

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

6 Expenditure on charitable activities

		Unrestricted funds		
	Note	General £	Total 2024 £	Total 2023 £
Staff costs	9	22,882	22,882	143,597
Allocated support costs		204,291	204,291	408,943
Governance costs	7	13,940	13,940	4,734
		<u>241,113</u>	<u>241,113</u>	<u>557,274</u>
		Activity support costs £	Total 2024 £	Total 2023 £
Fundraising costs		3,963	3,963	13,315
Advertising and marketing		9,019	9,019	8,219
Direct expenditure		(8,985)	(8,985)	14,118
Premises costs		1,808	1,808	13,265
Insurance		1,426	1,426	1,693
Finance costs		1,162	1,162	1,336
Motor and travel		2,173	2,173	3,443
Consulting		96,254	96,254	36,954
Entertainment		73	73	-
Staff costs		22,883	22,883	143,597
Staff training		-	-	3,500
Hire of equipment		457	457	658
Depreciation		2,698	2,698	9,955
Profit on disposal of fixed asset		(2,833)	(2,833)	-
Website and social media costs		16,328	16,328	12,897
Telephone and internet		7,305	7,305	6,008
Sundry		6,536	6,536	1,938
Interest payable		-	-	3,163
Event costs		-	-	33,000
Provision of medical equipment		-	-	118,233
Legal and professional		2,173	2,173	30,312
Exceptional admin costs		62,638	62,638	96,936
Printing, postage and stationery		1,463	1,463	-
Office expenses		632	632	-
Governance		13,940	13,940	4,734
		<u>241,113</u>	<u>241,113</u>	<u>557,274</u>

£241,113 (2023 - £557,274) of the above expenditure was attributable to unrestricted funds and £Nil (2023 - £Nil) to restricted funds.

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

7 Analysis of governance and support costs

Governance costs

	Unrestricted funds		
	General	Total	Total
	£	2024	2023
		£	£
Independent examiner fees			
Examination of the financial statements	3,300	3,300	3,300
Other fees paid to examiners	10,640	10,640	1,434
	<u>13,940</u>	<u>13,940</u>	<u>4,734</u>

8 Trustees remuneration and expenses

During the year the charity made the following transactions with trustees:

Gillian Nuttall

Gillian Nuttall received remuneration of £8,370 (2023: £68,480) during the year.

At the year end there was an amount due from Gillian Nuttall, a former trustee, of £17,776 (2023: £17,610). As this is unlikely to be recoverable, for accounting purposes this amount has been written off to exceptional administration expenses.

9 Staff costs

The aggregate payroll costs were as follows:

	2024	2023
	£	£
Staff costs during the year were:		
Wages and salaries	22,508	103,665
Social security costs	-	36,201
Pension costs	374	1,931
Other staff costs	-	1,800
	<u>22,882</u>	<u>143,597</u>

The monthly average number of persons (including senior management team) employed by the charity during the year expressed as full time equivalents was as follows:

	2024	2023
	No	No
Average number of employees including directors	<u>-</u>	<u>6</u>

The number of employees whose emoluments fell within the following bands was:

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

	2023 No
£60,001 - £70,000	<u><u>1</u></u>

The total employee benefits of the key management personnel of the charity were £Nil (2023 - £12,650).

10 Independent examiner's remuneration

	2024 £	2023 £
Examination of the financial statements	<u>3,300</u>	<u>3,300</u>
Other fees to examiners		
All other services	<u><u>10,640</u></u>	<u><u>1,434</u></u>

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

11 Taxation

The charity is a registered charity and is exempt from taxation of its income and gains falling within section 524 of the Income Tax Act 2007 to the extent that they are applied to its charitable objectives. No tax charge has arisen in the current and prior year.

12 Tangible fixed assets

	Furniture and equipment £	Motor vehicles £	Total £
Cost			
At 1 September 2023	6,268	52,688	58,956
Additions	2,790	-	2,790
Disposals	(5,888)	(52,688)	(58,576)
At 31 August 2024	3,170	-	3,170
Depreciation			
At 1 September 2023	6,040	23,051	29,091
Charge for the year	228	2,470	2,698
Eliminated on disposals	(5,888)	(25,521)	(31,409)
At 31 August 2024	380	-	380
Net book value			
At 31 August 2024	2,790	-	2,790
At 31 August 2023	228	29,637	29,865

13 Stock

	2024 £
Stocks	8,985

14 Debtors

	2024 £	2023 £
Accrued income	70,549	60,137
Other debtors	-	17,609
	70,549	77,746

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

15 Creditors: amounts falling due within one year

	2024 £	(As restated) 2023 £
Trade creditors	25,752	74,243
Other taxation and social security	(947)	82,341
Other creditors	-	4,393
Accruals	6,940	107,370
	<u>31,745</u>	<u>268,347</u>

16 Funds

	Balance at 1 September 2023 £	Incoming resources £	Resources expended £	Balance at 31 August 2024 £
Unrestricted funds				
General	261,260	285,944	(241,113)	306,091
Restricted funds				
Non Melanoma Skin Cancer	1,000	-	-	1,000
B-raf Awareness	3,562	-	-	3,562
Total restricted funds	4,562	-	-	4,562
Total funds	265,822	285,944	(241,113)	310,653

	Balance at 1 September 2022 £	Incoming resources £	Resources expended £	Transfers £	Balance at 31 August 2023 £
Unrestricted funds					
General	323,257	455,227	(557,274)	40,050	261,260
Restricted funds					
Mole Hunt	40,050	-	-	(40,050)	-
Non Melanoma Skin Cancer	1,000	-	-	-	1,000
B-raf Awareness	3,562	-	-	-	3,562
Total restricted funds	44,612	-	-	(40,050)	4,562
Total funds	367,869	455,227	(557,274)	-	265,822

Melanoma UK Limited

Notes to the Financial Statements for the Year Ended 31 August 2024

17 Analysis of net assets between funds

	Unrestricted funds	Restricted funds	Total funds
	General £	£	£
Tangible fixed assets	2,790	-	2,790
Current assets	324,634	4,562	329,196
Current liabilities	(31,745)	-	(31,745)
Total net assets	<u>295,679</u>	<u>4,562</u>	<u>300,241</u>